<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-148531</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Osteoporosis, estrogens and bone metabolism. Implications in chronic renal failure</dc:title>
<dc:description xml:lang="en">The relationship between estrogens, bone metabolism and osteoporosis is well known. Chronic renal failure in women is associated with menstrual disorders, lower bone mineral density and increased risk of fractures. However, most studies on renal osteodystrophy have not taken into account the role of oestrogen deficiency, its interaction, and the possible benefits of hormone replacement therapy (HRT) in uremic women. According to these limitations and the actual evidence of benefits and risks of HRT, we conclude that: a) Osteoporosis must be evaluated as a part of renal osteodystrophy; b) HRT would be considered in women with climateric symptoms and osteoporosis, and should not be used for prevention of cardiovascular disease, and c) Clearly we need to do more studies related to osteoporosis and estrogens in CRF, but right now we have to try to optimize bone turnover in our uremic patients (AU)</dc:description>
<dc:creator>Ramos, B</dc:creator>
<dc:creator>Díaz López, JB</dc:creator>
<dc:creator>Rodríguez Rodríguez, A</dc:creator>
<dc:creator>Cannata Andía, JB</dc:creator>
<dc:creator>Caramelo, C</dc:creator>
<dc:creator>Rodríguez García, M</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La relación entre estrógenos, metabolismo óseo y osteoporosis es bien conocida. En la mujer con insuficiencia renal crónica (IRC) se describen alteraciones menstruales precoces y un riesgo de osteoporosis y fracturas superior al observado en la población general. Sin embargo, los estudios relacionados con el déficit de estrógenos, su relación con la osteodistrofia renal y los posibles beneficios del tratamiento hormonal sustitutivo (THS) en la mujer urémica son escasos. Teniendo en cuenta las limitaciones señaladas y las nuevas evidencias respecto a los beneficios y riesgos del THS, concluimos: a) La osteoporosis debe de evaluarse como parte del estudio de la osteodistrofia renal; b) El THS se debería considerar en aquella mujer con síntomas climatéricos y osteoporosis, no estando hoy día indicado en la prevención de enfermedad cardiovascular, y c) Es clara la necesidad de realizar estudios relacionados con los estrógenos osteoporosis e IRC, entretanto, debemos tener una conducta activa con objeto de preservar el metabolismo óseo de nuestras pacientes con insuficiencia renal crónica (AU)</dc:description>
<dc:source>Nefrologia;23(supl.2): 78-83, 2003. tab</dc:source>
<dc:identifier>ibc-148531</dc:identifier>
<dc:title xml:lang="es">Osteoporosis, estrógenos y metabolismo óseo. Implicaciones en la insuficiencia renal crónica</dc:title>
<dc:subject>^d10205^s22012</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d5732^s22027</dc:subject>
<dc:subject>^d24823^s22044</dc:subject>
<dc:subject>^d8768^s22027</dc:subject>
<dc:subject>^d1867^s22044</dc:subject>
<dc:subject>^d33361^s22036</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d7851^s22044</dc:subject>
<dc:subject>^d14910^s22027</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d31161</dc:subject>
<dc:subject>^d1968^s22036</dc:subject>
<dc:subject>^d30131^s22036</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d10205^s22044</dc:subject>
<dc:subject>^d24823^s22057</dc:subject>
<dc:subject>^d24823^s22012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d7851^s22012</dc:subject>
<dc:subject>^d5732^s22054</dc:subject>
<dc:subject>^d24630^s22020</dc:subject>
<dc:subject>^d5059^s22031</dc:subject>
<dc:subject>^d2320^s22036</dc:subject>
<dc:subject>^d12501^s22027</dc:subject>
<dc:subject>^d5059^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>200300</dc:date>
</metadata>
</record>
</ibecs-document>
